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Abstract
Background: 22q11.2 deletion syndrome (22q11DS) is caused by a microdeletion on chromosome 22q11.2 and
associated with an increased risk to develop psychosis. The gene coding for catechol-O-methyl-transferase (COMT)
is located at the deleted region, resulting in disrupted dopaminergic neurotransmission in 22q11DS, which may
contribute to the increased vulnerability for psychosis. A dysfunctional motivational reward system is considered
one of the salient features in psychosis and thought to be related to abnormal dopaminergic neurotransmission.
The functional anatomy of the brain reward circuitry has not yet been investigated in 22q11DS.
Methods: This study aims to investigate neural activity during anticipation of reward and loss in adult patients with
22q11DS. We measured blood-oxygen-level dependent (BOLD) activity in 16 patients with 22q11DS and 12 healthy
controls during a monetary incentive delay task using a 3T Philips Intera MRI system. Data were analysed using SPM8.
Results: During anticipation of reward, the 22q11DS group alone displayed significant activation in bilateral middle
frontal and temporal brain regions. Compared to healthy controls, significantly less activation in bilateral cingulate
gyrus extending to premotor, primary motor and somatosensory areas was found.
During anticipation of loss, the 22q11DS group displayed activity in the left middle frontal gyrus and anterior cingulate
cortex, and relative to controls, they showed reduced brain activation in bilateral (pre)cuneus and left posterior cingulate.
Within the 22q11DS group, COMT Val hemizygotes displayed more activation compared to Met hemizygotes in right
posterior cingulate and bilateral parietal regions during anticipation of reward. During anticipation of loss, COMT Met
hemizygotes compared to Val hemizygotes showed more activation in bilateral insula, striatum and left anterior cingulate.
Conclusions: This is the first study to investigate reward processing in 22q11DS. Our preliminary results suggest that
people with 22q11DS engage a fronto-temporal neural network. Compared to healthy controls, people with 22q11DS
primarily displayed reduced activity in medial frontal regions during reward anticipation. COMT hemizygosity affects
responsivity of the reward system in this condition. Alterations in reward processing partly underlain by the dopamine
system may play a role in susceptibility for psychosis in 22q11DS.
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Background
Psychotic disorders, including schizophrenia, are poten-
tially devastating lifelong illnesses that are disabling and
costly to patients, families, communities and healthcare
systems. Symptoms typically emerge during late adoles-
cence, and the estimated lifetime prevalence and inci-
dence is approximately 0.3–0.7 % [1].
Treatment advances in these heterogeneous disorders
have been limited by insufficient mechanistic under-
standing of the underlying pathophysiology. Thus far,
pharmacological treatments have been based on the
premise of disrupted dopaminergic neurotransmission,
but the exact nature of dopamine (DA) dysregulation re-
mains complex [2].
One of the more recent theories of psychosis suggests
that an aberrant brain reward system could explain some of
the disorder’s clinical symptoms [3]. Anticipation of reward
represents motivational behaviour or drive (“wanting”),
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which is associated with activation of the typical cortical-
basal ganglia circuit [4] and particularly modulated by
dopamine in the ventral striatum. Consequently, dopa-
mine depletion results in lack of motivational drive,
apathy [5] and reduced brain activity in striatum and
cingulate gyrus during anticipation of reward [6], whereas
amphetamine-induced dopamine release in striatal brain
regions has been associated with pleasant emotions of
anticipation [5, 7]. Over recent years, several functional
magnetic resonance imaging (fMRI) studies have demon-
strated alterations in the brain reward network in patients
with, and at clinical high risk for, psychosis, primarily in
the striatal motivational system [8–13].
One of the most important proteins that regulate extra-
cellular brain dopamine concentrations is catechol-O-
methyl-transferase (COMT), an enzyme catabolising
released dopamine in cortical, particularly prefrontal,
areas [14]. A functional single nucleotide polymorphism,
Val158Met of the COMT gene (Val/Met), has been sug-
gested to lead to a 40 % reduction in enzyme activity and
has been shown to affect cortical DA metabolism levels,
with Val carriers displaying lower extracellular DA levels
than Met-carriers [15]. This polymorphism contributes to
measurable individual differences in human cognitive
function [16–18]. Moreover, fMRI studies in healthy par-
ticipants have shown that frontal and striatal activation
during anticipation of reward is dependent on COMT
genotype with Met homozygotes showing larger brain re-
sponse than Val homozygotes [19, 20].
Interestingly, the gene for COMT is located at chromo-
some 22q11.2, a chromosomal region that has received an
interest from psychiatric geneticists for over 20 years. A
deletion at 22q11.2 is the first and only copy number vari-
ant unequivocally implicated in psychotic disorders:
people with 22q11 deletion syndrome (22q11DS) carry a
25- to 30-fold increased risk of psychosis [21–23]. This
shared genetic variant that greatly increases risk for psych-
osis makes individuals with 22q11DS a relatively homoge-
neous population to study psychotic vulnerability. Thus,
22q11DS can provide unique insights into risk and pro-
tective factors for psychotic vulnerability that not only
benefit patients with 22q11DS but also could help patients
with psychosis that do not have this particular deletion.
COMT haplo-insufficiency in 22q11DS has been sug-
gested as one explanation for the increased susceptibility
for psychosis in 22q11DS. Indeed, it has been demon-
strated that people with 22q11DS have reduced COMT
gene expression [24, 25], enzyme activity [25] and alter-
ations in dopaminergic neurotransmission [26, 27]. Be-
cause of a paucity of dopamine transporter expression in
the frontal lobe, dopamine metabolism is largely depend-
ent on COMT in frontal brain regions. Therefore, effects
of reduced COMT gene dosage are expected to be most
pronounced in frontal brain regions in subjects with
22q11DS [25, 28]. In addition, the Val/Met polymorph-
ism may have a larger effect in 22q11DS because only
one copy of the allele is present, and COMT Met hemi-
zygotes may have extremely low COMT activity [15, 17,
25, 29, 30]. While COMT haplo-insufficiency has been
proposed as one explanation for the increased risk of
psychosis in 22q11DS, it should be noted that, overall,
the association between COMT genotype and psychosis
remains inconclusive [31–33].
The consequences of COMT haplo-insufficiency in
humans with 22q11DS at a neuronal level, and how this
relates to psychotic symptomatology is still unclear.
More specifically, the effect of the 22q11.2 deletion and
COMT haplo-insufficiency on reward processing is still
unknown. We therefore explored for the first time re-
ward processing in adults with 22q11DS using a reward
anticipation fMRI paradigm. We hypothesized that adults
with 22q11DS, because of their increased susceptibility for
psychosis, would not recruit brain regions that would nor-
mally be recruited during motivational behaviour. In
addition, we hypothesized that, in 22q11DS, brain activa-




Adult individuals with 22q11DS (n = 16) were recruited
through the Dutch 22q11DS family association and sev-
eral Dutch Clinical Genetics Centres. Healthy volunteers
(n = 12) were recruited by local advertisement as de-
scribed previously and are partially overlapping with the
healthy volunteers of our previous studies [6, 34]. The
study was conducted at the Department of Psychiatry,
Academic Medical Centre Amsterdam, The Netherlands,
and was approved by the local Medical Ethics Committee.
All participants were capable of giving written informed
consent and did so, after receiving full information on the
study. All individuals with 22q11DS were interviewed by a
physician using a semi-structured psychiatric interview.
Patients with 22q11DS with psychosis were all on anti-
psychotic medication and two 22q11DS patients without
psychosis were using selective serotonin reuptake inhibi-
tors (SSRIs) at the time of testing (Table 1). None of the
healthy participants had a history of psychiatric disorders,
medical conditions affecting brain function and substance
or alcohol abuse, and they were not using any medication
at the time of testing.
The Positive and Negative Symptom Scale (PANSS) [35]
was used to assess positive, negative and general psycho-
pathology in the 22q11DS group. In addition, for assess-
ment of intelligence quotient (IQ), we used the shortened
Dutch version of the Wechsler Adult Intelligence Scale
(WAIS-III-NL) consisting of five subtests: vocabulary,
comprehension, similarities (verbal IQ), block design and
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object assembly (performance IQ) [36, 37]. For demo-
graphics and clinical variables, see Table 1.
Genotyping
Blood samples were collected from all subjects with
22q11DS participants. DNA was isolated from blood using
standard procedures (Gentra Technology, Qiagen). Geno-
typing using 5′-nuclease Taqman assays for allelic discrim-
ination (Life Technologies, Foster City, California, USA)
was carried out with a LC-480 384-well Lightcycler
(Roche Diagnostics, Mannheim, Germany) [38]. COMT
Val158Met (rs4680) genotype was determined with Taq-
man assay C.25746809 A/G (Life Technologies). The
Lightcycler LC-480 Software release 1.5.0 was used to ana-
lyse end point fluorescence.
FMRI task: monetary incentive delay
We used event-related fMRI to assess blood-oxygen-
level dependent (BOLD) brain activation during the
monetary incentive delay (MID) task (Fig. 1) [39]. In
short, the MID task was used to evoke anticipation of
potential monetary reward, loss or no consequential out-
come. It consists of two sessions of 72 trials of 6 s, yield-
ing a total of 144 trials and total duration of 14 min.
During each trial, subjects were shown one of seven cues.
Cues signaling reward were denoted by circles (n = 54),
loss by squares (n = 54) and no monetary outcome by tri-
angles (n = 36). The amount of money that subjects were
able to win was indicated by one horizontal line (0.20
Euro), two lines (1.00 Euro) and three lines (5.00 Euros).
Similarly, loss cues signalled the possibility of losing the
same amounts of money. Subjects had to respond to the
white target square that appeared for a variable length of
time. To succeed in a trial, volunteers had to press the
button during the time that the white square target was
visible (target, 160–260 ms). Unlike the MID described by
Knutson et al. [35], we did not pay the amount of money
earned during the task; reward and loss was based on
point scoring [6, 34].
MRI data acquisition
FMRI data were collected using a 3T MRI Philips system
equipped with a sense head coil as previously explained
Table 1 Characteristics of participants
22q11DS (n = 16) Controls (n = 12) p
Age (SD) 28.2 (6) 29 (9.6) 0.79
Gender (M/F) 8/8 8/4 0.46
















Fig. 1 Monetary incentive delay task, structure for a representative trial
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[6, 34]. The task stimuli were generated using e-prime
software (SCOPE V2.5.4/Pentium). For the MID task
360 event related, transversal multi-slice T2*-weighted
gradient-echo planar images (EPI) were acquired with
echo time (TE) 30 ms, repetition time (TR) 2000 ms,
96 × 96 matrix, 35 slices, 3 × 3 mm in-plane resolution,
slice thickness 3 mm with a 1-mm interslice gap, cover-
ing the entire brain. For anatomical localization, trans-
versal high-resolution structural T1-weighted volumetric
images were acquired in the same session, with full head
coverage, using 150 contiguous slices (1-mm thick, with
0.89 × 0.89 mm in-plane resolution), a 256 × 256 × 124
matrix and a TR/TE of 24/5 ms (flip angle 45°, FOV
24 cm).
FMRI data analyses
All functional and structural brain images were pre-
processed with the researcher blind for group status, as
previously explained [6].
FMRI data pre-processing
Slice time correction was used to adjust for time differ-
ences due to multi-slice image acquisition. The func-
tional images were realigned to the first volume of the
time series to correct for head movements. After co-
registering functional images to the anatomical image,
they were spatially normalized to the standard space of
the Montreal Neurological Institute brain (MNI-brain).
All functional images were sub-sampled to a voxel size
of 2 × 2 × 2 mm. Normalized images were smoothed with
a Gaussian kernel of 8-mm full width at half maximum.
FMRI data statistical analysis
The analyses focused on changes in blood-oxygen-level
dependent (BOLD) contrast that occurred during antici-
patory delay periods and were conducted using SPM8
(Wellcome Department of Cognitive Neurology, London,
UK). The pre-processed fMRI data were analysed in the
context of the general linear model (GLM) approach [40]
using a two-level procedure.
At the first level, seven conditions (RewardHigh,
RewardMedium, RewardLow, Neutral, LossHigh, LossMedium,
Loslow) were modelled by a boxcar function convolved
with a hemodynamic response function. The movement
parameters were included as confounds in the design
matrix. Changes in the BOLD response were assessed
using the estimated GLM parameters for the anticipa-
tion of potential monetary gain vs. anticipation of no
monetary outcome (reward vs. neutral) and the anticipa-
tion of potential monetary loss vs. anticipation of no
monetary outcome (loss vs. neutral). In the second level
analysis, individual contrast images of the first level ana-
lysis were included in a two-sample t test to detect rele-
vant brain activation in patients with 22q11DS and in
healthy controls. Subsequently, within the 22q11DS group,
effects of COMT genotype and PANSS scores on brain ac-
tivation were tested. For the whole brain analysis, compar-
isons were corrected for multiple comparisons using
family wise error correction (FWEcor) p < 0.05 at the clus-
ter level (extent threshold of 10 voxels).
Results
Demographic characteristics
Patients with 22q11DS did not differ in age compared to
healthy controls (22q11DS 28.2 years ± 6.0 vs controls
29 years ± 9.6, p = 0.79). Also, gender distribution was
not significantly different between the two groups
(22q11DS M/F ratio 8/8; controls M/F ratio 8/4; p =
0.46, Fisher’s exact test). 22q11DS patients and healthy
controls differed in total IQ scores (HC 110 (10) and
22qDS 77 (10), p < 0.001). Within the 22q11DS group, 5
had a psychotic disorder, 6 were Val hemizygote and 10
were Met hemizygote (Table 1).
Task performance
Repeated measures ANOVA showed no significant main
effect of group (p = 0.25) on reaction time performance. Re-
action times in healthy controls in reward (243.4 ms ± 29.3)
and loss (250.7 ms ± 38.4) conditions did not differ from
those in patients with 22q11DS (reward 231.8 ms ± 29.2;
loss 230.1 ms ± 29.3). There was no main effect of incentive
value (p = 0.26) on reaction time performance and no sig-
nificant interaction effect (incentive value*group, p = 0.09).
FMRI results
Patients with 22q11DS
During anticipation of reward, patients with 22q11DS
significantly activated a large cluster (23,094 voxels) en-
compassing the bilateral middle frontal lobe and bilateral
middle and superior temporal lobe (pFWE < 0.001 cor-
rected for multiple comparisons at cluster level, Table 2).
During anticipation of loss, patients with 22q11DS showed
activation in a cluster (19786 voxels) including the left
middle frontal gyrus and the anterior cingulate cortex
(pFWE < 0.001, Table 2).
Within the 22q11DS group without psychosis (n = 11),
the same regions were found as in the total 22q11DS group
during anticipation of reward (same peak clusters, less sig-
nificant pFWE < 0.001 corrected) and during anticipation of
loss (same peak clusters, not significant (pFWE = 0.140)).
Within the 22q11DS group, there was no relation be-
tween PANSS scores and reward or loss related brain
activity.
Patients with 22q11DS vs. healthy controls
During anticipation of reward, patients with 22q11DS,
compared to controls, showed reduced activation (pFWE <
0.001) in a cluster (9271 voxels) covering the bilateral
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cingulate gyrus extending to premotor, primary motor and
somatosensory areas (Table 3, Fig. 2a). During anticipa-
tion of loss, patients with 22q11DS showed reduced activa-
tion (pFWE < 0.05) in a cluster (3147 voxels) encompassing
the left posterior cingulate cortex and extending bilaterally
to the cuneus and precuneus (Table 3, Fig. 2b).
22q11DS Val hemizygotes vs. 22q11DS Met hemizygotes
Within the 22q11DS group, anticipation of reward re-
sulted in more activation of the right posterior cingulate
and bilateral parietal regions in Val hemizygotes com-
pared to Met hemizygotes (cluster size 3008 voxels,
pFWE < 0.05, Table 4, Fig. 3a). Anticipation of loss resulted
Table 2 Peak level coordinates in the significant* cluster during anticipation of reward
Group Brain structure BA MNI coordinates T score
x y z
22q11DS L Hypothalamus NA −10 −6 −8 4.83
R Inferior frontal gyrus 47 26 18 −12 5.08
L Medial frontal gyrus 6 −10 −30 74 5.35
L Middle frontal gyrus 8 −24 20 48 4.53
R Middle frontal gyrus 10 34 50 0 4.53
L Middle temporal gyrus 21 −52 −46 4 4.37
R Middle temporal gyrus 21 54 −24 −12 4.64
R Putamen NA 28 −10 12 4.64
L Superior temporal gyrus 39 −34 −58 28 4.52
R Superior temporal gyrus 41 56 −20 4 4.63
Controls L Cingulate gyrus 24 −4 −10 40 7.79
R Cingulate gyrus 24 4 −12 40 7.26
R Cingulate gyrus 23 4 −16 34 6.96
R Cingulate gyrus 23 4 −32 28 5.52
R Cingulate gyrus 24 2 −18 44 9.02
R Cingulate gyrus 23 4 −12 30 5.64
R Middle occipital gyrus 18 32 −88 −8 7.39
L Posterior cingulate 23 −2 −30 24 9.25
R Precentral gyrus 4 20 −28 72 6.22
L Precuneus 31 −8 −62 22 5.73
R Precuneus 31 20 −78 26 6.58
R Superior frontal gyrus 6 6 16 68 5.69
L Transverse temporal gyrus 41 −42 −30 12 6.08
22q11DS > controls No significant results
Controls > 22q11DS L Cingulate gyrus 24 −4 −12 38 3.10
L Cingulate gyrus 24 −8 −20 40 3.24
R Cingulate gyrus 24 4 −12 40 4.63
R Cingulate gyrus 23 4 −30 28 3.28
R Cingulate gyrus 24 2 −20 40 5.03
R Cingulate gyrus 31 12 −32 42 3.24
R Medial frontal gyrus 6 10 −12 74 3.66
L Paracentral lobule 5 −8 −44 50 3.12
R Paracentral lobule 4 6 −42 72 3.10
R Postcentral gyrus 4 12 −38 60 4.60
L Precuneus 31 −2 −70 24 3.31
* p < 0.001 FWE- corrected at cluster level
L left, R right, BA Brodmann area
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in significantly more activation in the bilateral insula, stri-
atum and left anterior cingulate in Met hemizygotes
compared to Val hemizygotes (Cluster size: 4481 voxels,
Table 4, Fig. 3b).
Discussion
To our knowledge, this is the first study to investigate
the neural substrates of reward processing in people
with 22q11DS, a population at high risk of developing a
Table 3 Peak level coordinates in the significant* cluster during anticipation of Loss
Group Brain structure BA MNI coordinates T score
x y z
22q11DS L Cingulate gyrus 24 −6 −6 34 5.29
L Cingulate gyrus 24 −10 6 38 4.14
L Hippocampus NA −28 −22 −8 3.96
L Hypothalamus NA −8 −6 −10 5.44
R Medial frontal gyrus 6 10 0 66 4.14
L Middle frontal gyrus 6 −26 −4 64 4.34
L Middle frontal gyrus 11 −32 44 −8 4.07
R Middle frontal gyrus 6 30 10 60 3.93
R Middle frontal gyrus 10 34 38 22 6.04
Controls R Cingulate gyrus 24 2 −12 36 6.43
R Cingulate gyrus 24 2 −16 44 4.96
R Cingulate gyrus 24 10 −12 40 4.12
L Insula 13 −32 8 18 4.17
R Medial frontal gyrus 6 10 −14 54 4.99
R Medial frontal gyrus 6 10 −16 58 4.59
L Middle frontal gyrus 11 −30 36 −12 5.62
R Middle frontal gyrus 6 26 −18 66 4.75
R Middle frontal gyrus 9 28 32 32 4.59
R Precentral gyrus 4 20 −26 68 5.29
R Precentral gyrus 6 24 −16 74 4.08
R Superior temporal gyrus 41 48 −28 8 4.07
22q11DS > controls No significant results
Controls > 22q11DS L Cuneus 18 −4 −80 24 2.78
L Cuneus 18 −4 −90 12 2.74
L Cuneus 18 −10 −88 12 2.80
L Cuneus 18 −8 −84 20 3.06
R Cuneus 18 18 −84 26 3.62
R Cuneus 18 10 −82 26 2.84
R Cuneus 18 16 −86 16 3.01
R Cuneus 7 22 −84 32 2.95
R Cuneus 7 22 −80 28 3.00
L Middle occipital gyrus 19 −28 −82 14 2.89
L Posterior cingulate 23 −4 −54 22 2.86
L Precuneus 31 −2 −72 26 3.11
L Precuneus 31 −6 −68 24 3.20
L Precuneus 31 0 −78 24 2.81
L Precuneus 31 −24 −78 14 2.70
R Precuneus 7 14 −70 52 2.71
*p < 0.001 FWE-corrected at cluster level
L left, R right, BA Brodmann area
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psychotic illness. Our main fMRI findings suggest that
reward anticipation in 22q11DS engages a fronto-
temporal network. Compared to healthy controls, people
with 22q11DS primarily displayed reduced activity in
medial frontal regions during reward anticipation.
During anticipation of loss, a reduction in bilateral
(pre)cuneus and left posterior cingulate activity was
observed. Further analyses also revealed an effect of
COMT genotype on the 22q11DS reward anticipation
network.
The dysfunctional 22q11DS reward processing network
The 22q11DS reward anticipation network seems differ-
ent from healthy controls in several ways. During antici-
pation of reward, reduced activity in the cingulate gyrus
and medial frontal brain regions was observed. These
are all key structures of the reward circuitry in healthy
controls [4, 6, 39, 41–43].
Decreased cingulate gyrus activity during reward an-
ticipation could be related to impairments in predicting
reward outcome, since this region is related to predic-
tion error in reinforcement learning [44–46]. Reduced
activation in medial frontal brain regions in 22q11DS
during reward and posterior cingulate and (pre)cuneus
brain regions during loss may be a reflection or conse-
quence of the anatomical abnormalities typically seen in
people with 22q11DS. These alterations include grey
matter reductions in frontal and temporal regions and
widespread white matter reductions primarily in the pos-
terior lobe [47–51].
In contrast to other studies [11, 52], we were not able
to find significant activity in the ventral striatum during
reward processing, a core region of the reward network
[4, 11, 39, 53, 54]. This could be due to the small sample
size and the small area that includes the ventral stri-
atum. Moreover, the mixed gender group in our study
could have affected the results, since anticipation of
monetary reward differentially activates mesolimbic brain
regions in women compared to men [55].
Interestingly, similarities in the reward anticipation
network exist between 22q11DS and the schizophrenia
spectrum. In line with our findings in 22q11DS, previous
studies in unmedicated schizophrenia patients showed
reduced activity in the cingulate gyrus [49, 56] and a re-
cent study in siblings of schizophrenia patients, at in-
creased genetic risk for schizophrenia, found fronto-
striatal dysfunctioning during reward anticipation [57].
Behavioural studies furthermore found evidence for im-
paired functioning on reward tasks that depend on cor-
tical regions in people with schizophrenia, which is in
line with our results and suggested to be associated with
negative symptoms [58, 59]. Interestingly, the clinical
pattern in 22q11DS is also characterized by predominant
negative symptoms [60, 61].
The similarities in the reward network between 22q11DS
and schizophrenia spectrum may indicate that 22q11DS is
associated with similar behavioural impairments typically
seen in schizophrenia such as anhedonia, decreased motiv-
ation and a lack of reward sensitivity [11, 62–64]. Future
studies should further investigate the presence of these
symptoms in relation to the reward processing network in
22q11DS.
Lastly, it is interesting to speculate on the implications
of abnormal reward-related activity for the behavioural
phenotype in 22q11DS. This may suggest a decreased he-
donic component of reward anticipation and, as such,
could have implications for (risk of) addiction and sub-
stance abuse in 22q11DS [65]. Interestingly, in contrast to
schizophrenia patients [66] and the general population,
only a small percentage of 22q11DS patients suffer from
addiction and display substance abuse [60, 65, 67], possibly
suggesting aberrant reward sensitivity. The link between
abnormal reward-related brain activity and reward seeking
behaviour in 22q11DS requires further investigation.
Fig. 2 SPM t value for healthy controls vs. 22q11DS patients showing significant reduced BOLD activation in 22q11DS patients in the cingulate
cortex, primary motor and somatosensory areas during anticipation of reward (a) and in posterior cingulate cortex and cuneus during anticipation of
loss (b)
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COMT genotype effects on 22q11DS reward processing
In line with previous studies investigating reward antici-
pation with fMRI in healthy controls [19, 68], we found
an effect of COMT genotype on reward processing.
However, the present results should be considered pre-
liminary due to the small sample size of the COMT
genotype subgroups. We observed that the high-activity
Val allele compared to Met allele carriers was associated
with increased activity in posterior cingulate and parietal
regions during anticipation of reward. Whereas the low-
activity Met allele, compared to Val allele, was associated
with increased activity in the anterior cingulate cortex
and striatum during anticipation of loss. These results
are in line with previous fMRI research in 22q11DS
showing less efficient cingulate activity in Met-carriers,
during a response inhibition task [69]. This is further-
more supported by structural findings in 22q11DS adults
showing that the COMT Met allele was associated with
decreased frontal lobe volume [70], which is consistently
found to have abnormal functioning and structure in
22q11DS [47, 49]. While preliminary, these results are
noteworthy because they provide clues on the under-
lying reward-related alterations in neurochemical signal-
ing in 22q11DS, which could lead to more insight in
possible treatment targets [71].
Variation in COMT genotype has been associated with
altered cortico-striatal dopaminergic activity [72, 73].
22q11DS COMT hemizygosity has been associated with
decreased cortical COMT expression and enzyme activity,
possibly greatly increasing extracellular DA in 22q11DS
Met-carriers and moderately increasing extracellular DA
in 22q11DS Val carriers [24, 25].
Met-hemizygosity in 22q11DS is associated with worse
prefrontal cognitive functioning, possibly related to in-
creased levels of tonic DA and decreased phasic DA re-
lease [73, 74]. Alterations in DA function have previously
also been implicated to play a role in reward-related dys-
function and the development of psychotic symptoms in
schizophrenia [3, 7, 75]. Moreover, lower striatal mean
D2/3R binding has been found in Met hemizygotes, pos-
sibly reflecting higher synaptic DA levels [76]. All in all,
these findings may suggest that changes in dopamine
function might explain the effect of COMT genotype on
reward-related brain activity in frontal and striatal brain
regions in 22q11DS. This explanation, however, remains
speculative since the mechanism underlying COMT geno-
type effects on extracellular DA levels is thought to be far
more complex because of the different isoforms and the
suggested intracellular location of COMT [14, 77–79] and
our methods could not provide information on extracellu-
lar DA levels.
Lastly, the observation that brain activity associated
with anticipation of reward and loss was differentially
modulated by COMT genotype in 22q11DS may suggest
that COMT genotype impacts preferred reward engage-
ment strategies such as reward and loss seeking or aver-
sion behaviour. This idea is supported by previous work
hypothesizing that the Met genotype is associated with
higher loss aversion [68] and lower extraversion [80].
Limitations and future directions
A limitation of the study is the relatively small sample
size of the total and COMT specific sample, the presence
Table 4 Peak level coordinates in the significant* cluster during
anticipation of reward and loss in 22q11DS COMT Val and Met
hemizygotes
Reward-neutral
Group Brain structure BA MNI coordinates T score
x y z
Val > Met L Cingulate gyrus 31 −6 −48 34 2.77
L Cingulate gyrus 31 −4 −40 44 2.57
R Cingulate gyrus 23 4 −28 28 2.86
R Middle frontal gyrus 6 16 −8 62 2.63
R Paracentral lobule 4 6 −38 62 3.48
R Paracentral lobule 5 8 −42 58 2.99
L Postcentral gyrus 3 −20 −32 56 2.93
R Postcentral gyrus 3 10 −36 66 3.67
R Postcentral gyrus 3 24 −34 58 3.09
R Posterior cingulate 30 6 −46 20 2.59
R Precentral gyrus 4 32 −32 56 3.24
R Precentral gyrus 4 34 −30 68 3.05
R Precentral gyrus 4 26 −30 64 3.01
R Precentral gyrus 6 22 −24 68 2.73
L Precuneus 31 −10 −48 36 2.69
R Precuneus 7 12 −66 40 3.00
Met > Val No significant results
Loss-neutral
Group Brain structure BA MNI coordinates T score
x y z
Val > Met No significant results −
Met > Val L Anterior cingulate 24 −2 30 20 2.91
L Caudate body NA −12 −2 20 3.42
R Caudate body NA 10 −2 20 2.84
L Cingulate gyrus 23 −6 −34 28 3.58
L Cingulate gyrus 31 −16 −40 28 2.88
L Insula 13 −34 −6 16 2.86
L Posterior cingulate 23 −2 −40 22 3.29
L Putamen NA −24 −12 16 2.89
L Superior temporal gyrus 22 −64 −42 8 2.79
L Thalamus NA −18 −8 14 2.73
*p < 0.05 FWE-corrected at cluster level
L left, R right, BA Brodmann area
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of psychotic disorder in a part of the 22q11DS group and
the use of medication in some subjects, which could have
affected brain function [81]. We reanalysed a subset of the
22q11DS group excluding the 22q11DS subjects with
psychosis and replicated the majority of our prior fMRI
results, finding the same peak clusters in botch conditions.
However, in the anticipation of loss condition, the findings
did not survive the level of significance, which could be
the result of the smaller sample size. The present results
should therefore be considered preliminary and replica-
tion is needed. In light of the rarity of the disorder and the
challenge of recruitment, the sample size of the group
however could be considered acceptable.
Future research could address some other limitations
of this study. In line with previous studies that used a
point scoring system [34], our participants did not re-
ceive the actual money that they gained. Lack of a
powerful reinforcer such as money might have influ-
enced the participants’ motivation to perform to the best
of their abilities, possibly affecting activation patterns in
brain reward regions.
Furthermore, given that the BOLD signal is a hemo-
dynamic measure, the neurochemical mechanism behind
alterations in the 22q11DS reward network is unclear.
The observed between-group and COMT effects could
reflect changes in catecholaminergic activity or down-
stream consequences of these changes on other neuro-
transmitter systems. Positron emission tomography (PET)
studies in this disorder could be an important next step in
investigating the degree of dopaminergic abnormalities
during reward processing in 22q11DS.
Conclusions
This study is the first to investigate reward processing in
22q11DS. Our preliminary results suggest that people
with 22q11DS engage a fronto-temporal neural network
during reward processing and that, compared to con-
trols, brain activation within the 22q11DS group is re-
duced in medial and frontal brain regions.
Similarities with the reward neural network within the
schizophrenia spectrum were observed, which is in line
with the clinical overlap between the behavioural impair-
ments typically seen in 22q11DS and schizophrenia.
Our findings may be explained by the anatomical ab-
normalities typically seen in 22q11DS or by the COMT
haplo-insufficiency in 22q11DS, which is hypothesized
to result in primarily abnormal frontal DA levels and in-
creased extracellular DA release in low-activity Met hemi-
zygotes. In line with this notion, an effect of 22q11DS
COMT genotype on reward processing was additionally
observed, which may provide further clues on the under-
lying reward-related alterations in neurochemical signal-
ing in 22q11DS and its possible relevance for psychotic
disorder.
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